EGFR and breast carcinoma: In this study, we demonstrated that proteasome inhibitor bortezomib reduces the viability of HER2-positive breast cancer cells and their lapatinib resistance clones through suppressing HSP90 function to induce the degradation of ErbB members via the autophagy-lysosomal pathway.